ACURA PHARMACEUTICALS, INC Reports $200K Loan; Secured Debt $11.09M

What Happened

• Acura Pharmaceuticals filed an 8-K disclosing that on August 14, 2026 it received a $200,000 loan from Abuse Deterrent Pharma, LLC (AD Pharma). The loan, combined with prior loans and the $2,319,279 balance under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, results in a principal secured debt balance of $11,094,279 and accrued interest of approximately $1,290,000 as of August 14, 2026. The Note bears interest at 5.25% (default interest 7.5%).

Key Details

• Lender: Abuse Deterrent Pharma, LLC; new loan amount: $200,000 (funds used for day-to-day operations).
• Total principal under secured note: $11,094,279; accrued interest: ~ $1,290,000 (as of Aug 14, 2026).
• Interest rate: 5.25% annual; overdue/default interest: 7.5% per annum from date of non-payment.
• Events of default include bankruptcy, failure to pay principal or interest (with a 5‑day cure for certain failures), and inability to pay debts. Company warned that without additional financing by late‑September 2026 it may need to scale back or cease operations.

Why It Matters

• This filing shows Acura is relying on short-term loans to fund operations and now carries over $11 million of secured debt plus substantial accrued interest. The company explicitly warns it needs more financing by late‑September 2026 or faces furloughs, layoffs, operational scale-backs, potential termination of operations, or bankruptcy—outcomes that could materially harm shareholders. Investors should monitor Acura’s near-term financing progress, debt terms, and any further disclosures about renegotiation or refinancing.